Back to Journals » Core Evidence » Volume 9

Eptifibatide: The evidence for its role in the management of acute coronary syndromes [Corrigendum]

Authors Shah I, Khan SO, Malhotra S, Fischell T

Received 12 March 2014

Accepted for publication 12 March 2014

Published 14 March 2014 Volume 2014:9 Pages 49—50

DOI https://doi.org/10.2147/CE.S63964


Shah I, Khan SO, Malhotra S, Fischell T. Core Evidence. 2009;4:49–65.

Note that on pages 56 and 57, in the legends of both Table 3 and Table 4, the definition of TIMI is incorrectly stated as "TIMI, thrombosis in MI". The correct legend should state "TIMI, thrombolysis in myocardial infarction".
On page 61, in line 6 of the first paragraph, note that "unadjusted heart rate" is incorrect, and should be "unadjusted hazard ratio".

Read the original article.

Note that on pages 56 and 57, in the legends of both Table 3 and Table 4, the definition of TIMI is incorrectly stated as “TIMI, thrombosis in MI”. The correct legend should state “TIMI, thrombolysis in myocardial infarction”.

On page 61, in line 6 of the first paragraph, note that “unadjusted heart rate” is incorrect, and should be “unadjusted hazard ratio”.

On page 62, the last sentence is incorrectly provided as follows: “Given that the combination of abciximab plus reduced-dose fibrinolytic was associated with a significantly higher incidence of major and minor bleeding than treatment with a fibrinolytic [GUSTO-V76 and ASSENT-3,77 studies that are sufficiently powered for tolerability endpoints are required before firm conclusions can be drawn regarding the effect of a combination of eptifibatide and reduced-dose fibrinolytic on the incidence of major hemorrhage”. The correct sentence is: “Given that the combination of abciximab plus a reduced dose of fibrinolytic was associated with a significantly higher incidence of major and minor bleeding than treatment with a fibrinolytic agent alone [GUSTO-V76 and ASSENT-377] studies that are sufficiently powered for tolerability endpoints are required before firm conclusions can be drawn regarding the effect of a combination of eptifibatide and reduced-dose fibrinolytic”.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]